Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT

  • Authors:
    • Rong Li
    • Changli Wu
    • Hongying Liang
    • Yinghai Zhao
    • Chunyan Lin
    • Xiujuan Zhang
    • Caiguo Ye
  • View Affiliations

  • Published online on: July 20, 2018     https://doi.org/10.3892/ijo.2018.4495
  • Pages: 1763-1773
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The transcription factor twist family bHLH transcription factor 1 (TWIST), which is a member of the basic helix-loop-helix class of proteins, is known to induce epithelial-mesenchymal transition (EMT) and promote cancer metastasis. TWIST has previously been reported to be associated with multidrug resistance (MDR), since its depletion increases drug sensitivity. Although these previous studies have established a strong association between EMT and MDR, the molecular mechanism remains obscure. The present study demonstrated that TWIST protein expression was elevated in liver cancer, and was positively correlated with multidrug resistance protein 1 (MDR1) expression. Conversely, MDR1 was negatively correlated with E‑cadherin expression in liver cancer samples. In addition, the present study indicated that doxorubicin-resistant HepG2 (R‑HepG2) cells acquired an EMT phenotype. TWIST was also more highly expressed in R‑HepG2 cells compared with in parental HepG2 cells. Knockdown of TWIST increased the sensitivity of R‑HepG2 cells to 5-fluroracil, cisplatin and doxorubicin through a reduction in MDR1 expression and drug efflux ability. Furthermore, knockdown of TWIST in R‑HepG2 cells inhibited the migratory ability of cells and suppressed the EMT phenotype. These findings demonstrated that targeting TWIST may be considered a novel strategy to overcome drug resistance in liver cancer.

References

1 

Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K and Saitsu H: Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients. OncoTargets Ther. 8:3193–3202. 2015. View Article : Google Scholar

2 

Zender L, Villanueva A, Tovar V, Sia D, Chiang DY and Llovet JM: Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 52:921–929. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P and Frenette C: Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol. 6:469–478. 2015.PubMed/NCBI

4 

Song MJ and Bae SH: Newer treatments for advanced hepatocellular carcinoma. Korean J Intern Med (Korean Assoc Intern Med). 29:149–155. 2014.

5 

Follit CA, Brewer FK, Wise JG and Vogel PD: In silico identified targeted inhibitors of P-glycoprotein overcome multidrug resistance in human cancer cells in culture. Pharmacol Res Perspect. 3:e001702015. View Article : Google Scholar : PubMed/NCBI

6 

McCormick JW, Vogel PD and Wise JG: Multiple drug transport pathways through human P-glycoprotein. Biochemistry. 54:4374–4390. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Janigro D, Perju C, Fazio V, Hallene K, Dini G, Agarwal MK and Cucullo L: Alternating current electrical stimulation enhanced chemotherapy: A novel strategy to bypass multidrug resistance in tumor cells. BMC Cancer. 6:722006. View Article : Google Scholar : PubMed/NCBI

8 

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al: EMT and dissemination precede pancreatic tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Vesuna F, Bergman Y and Raman V: Genomic pathways modulated by Twist in breast cancer. BMC Cancer. 17:522017. View Article : Google Scholar : PubMed/NCBI

10 

Tang H, Massi D, Hemmings BA, Mandalà M, Hu Z, Wicki A and Xue G: AKT-ions with a TWIST between EMT and MET. Oncotarget. 7:62767–62777. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Zhang H, Gong J, Kong D and Liu HY: Anti-proliferation effects of Twist gene silencing in gastric cancer SGC7901 cells. World J Gastroenterol. 21:2926–2936. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Nantajit D, Lin D and Li JJ: The network of epithelial-mesen-chymal transition: Potential new targets for tumor resistance. J Cancer Res Clin Oncol. 141:1697–1713. 2015. View Article : Google Scholar

13 

Jiang ZS, Sun YZ, Wang SM and Ruan JS: Epithelial-mesenchymal transition: Potential regulator of ABC transporters in tumor progression. J Cancer. 8:2319–2327. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Deng JJ, Zhang W, Xu XM, Zhang F, Tao WP, Ye JJ and Ge W: Twist mediates an aggressive phenotype in human colorectal cancer cells. Int J Oncol. 48:1117–1124. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Liu YR, Liang L, Zhao JM, Zhang Y, Zhang M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters. Oncotarget. 8:52901–52912. 2017.PubMed/NCBI

16 

Lu S, Yu L, Mu Y, Ma J, Tian J, Xu W and Wang H: Role and mechanism of Twist1 in modulating the chemosensitivity of FaDu cells. Mol Med Rep. 10:53–60. 2014. View Article : Google Scholar : PubMed/NCBI

17 

López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Zhang X, Wu C, Xiong W, Chen C, Li R and Zhou G: Knockdown of p54nrb inhibits migration, invasion and TNF-α release of human acute monocytic leukemia THP1 cells. Oncol Rep. 35:3742–3748. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Li R, Zhao Y, Chen J, Shao S and Zhang X: Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells. Mol Med Rep. 9:413–418. 2014. View Article : Google Scholar

20 

de Jong E, Winkel P, Poelstra K and Prakash J: Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: Novel actions on SIRT1 and HDAC. PLoS One. 6:e251922011. View Article : Google Scholar : PubMed/NCBI

21 

Zhuo X, Chang A, Huang C, Yang L, Xiang Z and Zhou Y: Expression of TWIST, an inducer of epithelial-mesenchymal transition, in nasopharyngeal carcinoma and its clinical significance. Int J Clin Exp Pathol. 7:8862–8868. 2014.

22 

Zhang YQ, Wei XL, Liang YK, Chen WL, Zhang F, Bai JW, Qiu SQ, Du CW, Huang WH and Zhang GJ: Over-expressed Twist associates with markers of epithelial mesenchymal transition and predicts poor prognosis in breast cancers via ERK and Akt activation. PLoS One. 10:e01358512015. View Article : Google Scholar : PubMed/NCBI

23 

Chun HW and Hong R: Significance of the hedgehog pathway-associated proteins Gli-1 and Gli-2 and the epithelial-mesenchymal transition-associated proteins Twist and E-cadherin in hepatocellular carcinoma. Oncol Lett. 12:1753–1762. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Yang L, Hou Y, Yuan J, Tang S, Zhang H, Zhu Q, Du YE, Zhou M, Wen S, Xu L, et al: Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget. 6:25755–25769. 2015.PubMed/NCBI

25 

Zhou Y, Zhang H, Zhuo X, Liu Y, Zhang G and Tan Y: Over-expression of TWIST, an epithelial-mesenchymal transition inducer, predicts poor survival in patients with oral carcinoma. Int J Clin Exp Med. 8:9239–9247. 2015.PubMed/NCBI

26 

Zhu K, Chen L, Han X and Wang J and Wang J: Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells. Oncol Rep. 27:1027–1034. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Shi XP, Miao S, Wu Y, Zhang W, Zhang XF, Ma HZ, Xin HL, Feng J, Wen AD and Li Y: Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int J Mol Sci. 14:15655–15668. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Song J and Li Y: miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. Cancer Sci. 108:23–31. 2017. View Article : Google Scholar

29 

Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X, Wang Z, Yang Y, Chen C, Wang Z, et al: The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 6:7000–7010. 2015.PubMed/NCBI

30 

Ye CG, Yeung JH, Huang GL, Cui P, Wang J, Zou Y, Zhang XN, He ZW and Cho CH: Increased glutathione and mitogen-activated protein kinase phosphorylation are involved in the induction of doxorubicin resistance in hepatocellular carcinoma cells. Hepatol Res. 43:289–299. 2013. View Article : Google Scholar

31 

Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong CC, Ren SX, Zhang L, Fung KP and Cho CH: Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett. 304:90–96. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Sun J, Yeung CA, Co NN, Tsang TY, Yau E, Luo K, Wu P, Wa JC, Fung KP, Kwok TT, et al: Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell line. PLoS One. 7:e407202012. View Article : Google Scholar

33 

Jin S and Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol. 18:4377–4384. 1998. View Article : Google Scholar : PubMed/NCBI

34 

Zou Z, Zou R, Zong D, Shi Y, Chen J, Huang J, Zhu J, Chen L, Bao X, Liu Y, et al: miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 21:1929–1943. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Feng R and Dong L: Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells. Int J Clin Exp Pathol. 8:6107–6116. 2015.PubMed/NCBI

36 

Ma H, Yue X, Gao L, Liang X, Yan W, Zhang Z, Shan H, Zhang H, Spear BT and Ma C: ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. Oncotarget. 6:1049–1063. 2015. View Article : Google Scholar :

37 

Saxena M, Stephens MA, Pathak H and Rangarajan A: Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2:e1792011. View Article : Google Scholar : PubMed/NCBI

38 

Chao HM, Huang HX, Chang PH, Tseng KC, Miyajima A and Chern E: Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway. Oncotarget. 8:2604–2616. 2017. View Article : Google Scholar

Related Articles

Journal Cover

October 2018
Volume 53 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, R., Wu, C., Liang, H., Zhao, Y., Lin, C., Zhang, X., & Ye, C. (2018). Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT. International Journal of Oncology, 53, 1763-1773. https://doi.org/10.3892/ijo.2018.4495
MLA
Li, R., Wu, C., Liang, H., Zhao, Y., Lin, C., Zhang, X., Ye, C."Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT". International Journal of Oncology 53.4 (2018): 1763-1773.
Chicago
Li, R., Wu, C., Liang, H., Zhao, Y., Lin, C., Zhang, X., Ye, C."Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT". International Journal of Oncology 53, no. 4 (2018): 1763-1773. https://doi.org/10.3892/ijo.2018.4495